Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Treasury Shares (2020 - 2025)

Heron Therapeutics (HRTX) has disclosed Treasury Shares for 6 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 91.77% year-over-year to $3.8 million, compared with a TTM value of $3.8 million through Dec 2025, up 91.77%, and an annual FY2025 reading of $3.8 million, up 91.77% over the prior year.
  • Treasury Shares was $3.8 million for Q4 2025 at Heron Therapeutics, down from $4.0 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.8 billion in Q3 2023 and bottomed at $570000.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $91.6 million, with a median of $2.6 million recorded in 2022.
  • The sharpest move saw Treasury Shares skyrocketed 63301.53% in 2023, then crashed 99.91% in 2024.
  • Year by year, Treasury Shares stood at $2.8 million in 2021, then increased by 12.99% to $3.2 million in 2022, then plummeted by 55.64% to $1.4 million in 2023, then surged by 41.0% to $2.0 million in 2024, then skyrocketed by 91.77% to $3.8 million in 2025.
  • Business Quant data shows Treasury Shares for HRTX at $3.8 million in Q4 2025, $4.0 million in Q3 2025, and $4.1 million in Q2 2025.